ASN Foundation for Kidney Research

Biographies

Joseph A. Carlucci

Joseph A. Carlucci

Mr. Joseph A. Carlucci serves as Co-Founder, Chairman, and Chief Executive Officer at American Renal Associates LLC. He has more than 30 years of experience in the dialysis services industry and is the former President and CEO of Optimal Renal Care, a joint venture in disease management between Fresenius Medical Care North America (FMCNA) and Kaiser Permanente of Southern California. Prior to Optimal, Mr. Carlucci was Vice President of Administration at Fresenius and responsible for managed care, medical director relations, and facility development. He has considerable operations experience from Facility Administrator to Director of U.S. Operations. He received his B.S. degree in Accounting from Bentley College.

Mr. Carlucci has spent more than 30 years focusing on improving care for dialysis patients. In 1999, he co-founded American Renal Associates, modeling unique partnerships with practicing nephrologists. He is a strong advocate for involving physicians at the local level to promote excellence in patient care for dialysis patients. American Renal Associates and Mr. Carlucci believe vesting physicians and other kidney professionals in setting and reaching the highest standards of patient care is the optimum model for providing this life-saving treatment to the more than 400,000 Americans with kidney failure.

Mr. Carlucci has developed systems that produce better clinical outcomes and improved physician and patient satisfaction in cost-conscious environments. His word demonstrates that operating effective, high-quality ESRD care programs produce cost savings by improving the health of ESRD patients, thus ensuring that fewer resources will be required. He also has innovated key solutions to patient care challenges using multidisciplinary care teams and patient education programs.

The Joseph A. Carlucci Research Fellowship will extend Mr. Carlucci's patient-centered vision by supporting groundbreaking kidney research and advancing treatment for the millions of people with kidney disease.